<DOC>
	<DOCNO>NCT02309957</DOCNO>
	<brief_summary>Prospective , multi-center , non-randomized , historical control , post-market study patient require surgical repair focal articular cartilage lesion osteochondral defect knee .</brief_summary>
	<brief_title>EAGLE European Post Market Study</brief_title>
	<detailed_description>BioMatrix CRD CE mark device intend repair focal articular cartilage lesion osteochondral defect knee . BioMatrix CRDâ„¢ sterile , biphasic , bioresorbable scaffold design aid repair cartilage subchondral bone . The device serve scaffold cellular extracellular matrix ingrowth support regeneration cartilage subchondral bone . The purpose post-market study confirm safety performance BioMatrix CRD intend use . Fifty ( 50 ) patient enrol 10 hospital Europe . Patients follow 2 year post-operative examine rate adverse event associate device , track improvement knee pain knee function time , assess quality repair tissue .</detailed_description>
	<criteria>Preprocedure KOOS Pain subscale score less equal 70 . ICRS grade 3 4 focal articular cartilage lesion medial femoral condyle , lateral femoral condyle trochlea , measure less equal to15mm diameter . Cartilage lesion amenable treatment single BioMatrix CRD osteochondral autograft . Previous cartilage repair procedure ( i.e. , microfracture , OATS , ACI ) intend implantation site . Clinically significant ( &gt; 5 degree ) varus valgus malalignment either knee . Osteoarthritis injured knee . Inflammatory arthropathy Osteomyelitis active infection either low limb . Cortisone hyaluronic acid knee injection past 3 month Body mass index great 35 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Knee Cartilage Repair , Osteochondral Defects , BioMatrix CRD</keyword>
</DOC>